From October through November 2026, our research team reviewed published research on travel to opioid treatment, federal guidance on privacy and medication access, and safety findings related to anesthesia-assisted detoxification. In the sections below, we break down the measured travel baseline, discretion and privacy needs, local substance trends, aftercare infrastructure, physician staffing and safety credentials, and what the data means for patients and families, along with talking with a physician-led team in Michigan.
What Does the Research Measure About Out-of-State Travel?
The percentage of rapid detox patients who travel out of state is not established by the sources reviewed for this article. The closest measured baseline in these sources concerns people entering methadone treatment at opioid treatment programs, not people undergoing rapid detox.
Rosenblum and colleagues studied 23,141 patients entering 84 opioid treatment programs in 34 states. Data were collected from January 2005 through December 2009. The study reported that 8% crossed a state border to attend their program.
| Measured finding | Reported result | Scope and source |
|---|---|---|
| Cross-state commuting | 8% of patients | Methadone treatment enrollees, not rapid detox patients. Rosenblum study |
| Distance among interstate patients | Mean 50 miles; median 36 miles | Distances among patients who crossed a state border. Rosenblum study |
| Overall travel distance | Median 7 miles | All patients in the study, not just interstate travelers. Rosenblum study |
These findings are historical, not a current rate. Programs were selected partly from areas where prescription opioid misuse was thought to be prevalent, so the sample was not nationally representative. Crossing a nearby state border is also different from traveling across the country. The study cannot establish whether rapid detox patients travel out of state more often.
Discretion and Privacy Needs
Privacy can be a question when someone considers treatment away from home, but the sources reviewed do not measure how often privacy causes rapid detox patients to cross state lines. An occupation or public profile is not a basis for assigning a travel percentage.
| Privacy issue | What the source establishes | Question to ask |
|---|---|---|
| Confidential treatment records | HHS explains that 42 CFR Part 2 protects records from covered substance use disorder programs. | Which confidentiality rules apply to this program and my records? |
| Consent to share information | The HHS fact sheet describes consent for treatment, payment, and health care operations, with specific protections for certain other uses. | Who may receive information under the consent forms I sign? |
| Use in proceedings against a patient | HHS states that patient records cannot be used to investigate or prosecute the patient without written consent or a qualifying court order. | How are requests for my records handled? |
Travel does not itself guarantee confidentiality. Ask about billing, communication with family members, and coordination with local clinicians before deciding where to receive treatment.
Local Substance Trends
The substances a person uses affect the questions a clinician needs to address. They do not supply a reliable out-of-state travel percentage. The reviewed sources do not establish travel rates for people using fentanyl, heroin, prescription opioids, methadone, buprenorphine, tramadol, or concentrated kratom-derived products.
| Substance or treatment issue | Source-backed finding | What to discuss before travel |
|---|---|---|
| Concentrated 7-OH products | FDA warns that products with added or enhanced 7-hydroxymitragynine can cause addiction and withdrawal symptoms and have not been proven safe or effective for any use. | Tell the physician exactly which products you use and bring available labeling. |
| Buprenorphine treatment | SAMHSA explains that the special federal waiver to prescribe buprenorphine for opioid use disorder has been eliminated. State requirements still apply. | Check local treatment availability rather than assuming an older provider directory is complete. |
| Methadone and buprenorphine as treatment options | CDC identifies medication treatment as an evidence-based approach to opioid dependence. | Discuss continued medication treatment and other options before choosing detoxification. |
The FDA warning distinguishes enhanced 7-OH products from the trace amounts naturally present in kratom. It is a safety warning, not a measure of interstate travel. This article does not use state bans or changes in overdose deaths to calculate demand for rapid detox.
Aftercare Infrastructure
Access to continuing care is relevant whether treatment happens locally or in another state. Historical research documents geographic gaps in medication access, but those gaps do not tell us how many rapid detox patients travel.
| Measured access finding | Population and period | Source and limitation |
|---|---|---|
| 56.3% of rural counties lacked a waivered provider | Counties at the end of 2017 | Andrilla et al. measured providers under the former buprenorphine waiver system. |
| 29.8% of rural residents lived in a county without a provider | Rural population at the end of 2017 | Andrilla et al. reported residents, not the share of counties or patients traveling. |
| 2.2% of urban residents lived in a county without a provider | Urban population at the end of 2017 | Andrilla et al. provides an urban comparison from the same study. |
| 597 of 3,143 counties, or 19%, had neither provider type | U.S. counties in 2022 | Axios reporting on the OIG review identifies office-based buprenorphine providers and opioid treatment programs, not all addiction services. |
These are snapshots from different periods and should not be treated as current provider counts or as a trend measured with a single method. SAMHSA states that the federal buprenorphine waiver requirement was removed in December 2022. The OIG review also found that provider presence did not always mean access for Medicare or Medicaid enrollees.
Before traveling, identify who will prescribe medication, provide follow-up, and respond to problems after you return home. Ask whether the local clinician has agreed to accept you and whether appointments and coverage are confirmed.
Physician Staffing and Safety Credentials
Safety needs a separate discussion from convenience. A CDC investigation of a New York City clinic found that, among 75 patients who underwent anesthesia-assisted rapid opioid detoxification in 2012, two died and five others had serious adverse events requiring hospitalization. CDC reported a serious adverse event rate of 9.3% at that clinic.
That investigation is not a nationwide complication rate and does not establish the risk at All Opiates Detox. It does document serious risks. CDC reported that professional societies, including the American Society of Addiction Medicine, recommended against anesthesia-assisted rapid detoxification. CDC favored evidence-based medication treatment and found little to no evidence supporting this procedure.
| Credential or care process to ask about | Why it matters | Source-backed note |
|---|---|---|
| Anesthesia qualifications and monitoring | Clarifies who manages sedation, breathing, and recovery. | CDC described cardiac arrests, pulmonary edema, and aspiration in the investigated cases. Credentials do not eliminate these risks. |
| Addiction medicine evaluation | Supports a discussion of treatment choices, not only withdrawal management. | CDC identifies medication treatment as a preferred evidence-based approach. |
| Medical and substance-use screening | Allows an individual assessment before a treatment decision. | CDC reported polysubstance use in 35% of the investigated clinic population. |
| Mental health assessment | Helps identify psychiatric needs and arrange appropriate care. | CDC reported psychiatric disorders in 55% of the investigated clinic population. |
| Electrolyte assessment and management | Addresses a potentially serious medical problem. | CDC attributed a death in the investigation to hypokalemia and cardiac arrhythmia following the procedure. |
| Emergency response and hospital transfer planning | Explains what happens if a patient deteriorates. | CDC documented hospital transfers after serious complications. Hospital proximity alone does not establish safety. |
| Recovery monitoring and discharge criteria | Clarifies when travel is medically appropriate. | CDC documented serious events during and after recovery despite overnight monitoring. |
| Continuing treatment and physician follow-up | Keeps the focus on ongoing opioid use disorder care. | CDC states that detoxification has negligible effects on long-term abstinence without longer-term evidence-based treatment. |
This is a discussion guide, not a validated safety checklist or a ranking of providers. Ask a qualified clinician to explain the benefits, risks, alternatives, and suitability of any proposed treatment before making travel arrangements.
What the Methadone Data Means for Patients and Families
The defensible travel finding is the historical 8% reported among methadone treatment enrollees in the Rosenblum study. There is no supported rapid detox travel percentage to compare with it. Privacy, local services, ongoing care, and staffing are planning considerations, not measured causes of interstate rapid detox travel in the sources reviewed.
Detoxification is not the same as ongoing treatment for opioid use disorder. CDC emphasizes the need for longer-term evidence-based care. Discuss methadone, buprenorphine, or naltrexone as clinically appropriate, along with counseling and other support. Do not stop prescribed medication just to make a travel schedule work.
Before booking, confirm medical eligibility, the treatment plan, discharge requirements, a support person if needed, and follow-up at home. Ask the treating clinician when it is appropriate to fly or drive. A brief advertised program does not guarantee that every patient will be ready to travel on the same schedule.
Talk With a Physician-Led Team in Michigan
All Opiates Detox is in Wyandotte, Michigan. Its About Us page identifies Dr. Joseph George as board-certified in addiction medicine and Dr. Jibran Attiq as a board-certified anesthesiologist. Its FAQ describes treatment by two board-certified physicians at a state-licensed facility next to Henry Ford Wyandotte Hospital.
The FAQ advertises a three-day program, unlimited physician aftercare, and direct physician phone numbers for follow-up after discharge. These are the practice’s descriptions of its services, not independently measured outcomes. Confirm the expected length of stay, support arrangements, and any limits before you book.
The AOD homepage describes an admission evaluation to determine safety and eligibility. Ask the team to explain whether the procedure is appropriate for you, how its risks compare with medication treatment, and how continuing care will be arranged. Do not assume that Vivitrol will be given before discharge; confirm the medication, formulation, and timing with the physician.
Contact All Opiates Detox to speak directly with Dr. Joseph George, MD, at (800) 458-8130.
Sources
- Rosenblum et al. Distance Traveled and Cross-State Commuting to Opioid Treatment Programs.
- HHS. Fact Sheet: 42 CFR Part 2 Final Rule.
- FDA. Products Containing 7-OH Can Cause Serious Harm.
- Andrilla et al. Geographic distribution of providers with a DEA waiver to prescribe buprenorphine: a 5-year update. University of Washington research abstract.
- HHS Office of Inspector General. Medicare and Medicaid Enrollees in Many High-Need Areas May Lack Access to Medications for Opioid Use Disorder.
- Axios. Opioid abuse treatments do not reach areas most in need. Reporting on the HHS OIG review.
- SAMHSA. Waiver Elimination (MAT Act).
- CDC. Deaths and Severe Adverse Events Associated with Anesthesia-Assisted Rapid Opioid Detoxification: New York City, 2012.
- All Opiates Detox. About Us.
- All Opiates Detox. Frequently Asked Questions.
- All Opiates Detox. Homepage.